Literature DB >> 9537577

Aberrant FHIT transcripts in squamous cell carcinoma of the uterine cervix.

K Yoshino1, T Enomoto, T Nakamura, R Nakashima, H Wada, J Saitoh, K Noda, Y Murata.   

Abstract

The fragile histidine triad (FHIT) tumor suppressor gene at 3p14.2 has abnormalities in several types of human cancers. To investigate the potential role of FHIT in cervical cancer, which exhibits frequent loss of heterozygosity of 3p, we have examined primary cervical cancer samples from 28 patients for alterations of the FHIT gene. Abnormal FHIT transcripts were detected using reverse transcription-polymerase chain reaction (PCR) and subsequently by sequencing. Of 28 primary cervical carcinomas analyzed, 12 tumors (43%) showed abnormal FHIT transcripts, including deletion, insertion and point mutation. Loss of a FHIT transcript was observed in 2 cases (7%). Allelic loss of the FHIT gene was detected in 16 of 27 informative cases (59%). Oncogenic human papillomavirus (HPV) type 16, 18, 33, 35, 58 and 59 were not only present but were expressed in 24 of 28 cases (85%) by consensus PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) analysis for the HPV E6 and E7 genes. Our data indicate that alteration of the FHIT gene is an important genetic event associated with cervical cancer and oncogenic

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537577     DOI: 10.1002/(sici)1097-0215(19980413)76:2<176::aid-ijc2>3.0.co;2-u

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients.

Authors:  Po Zhao; Wu Liu; Ya-Li Lu
Journal:  World J Gastroenterol       Date:  2005-09-28       Impact factor: 5.742

2.  FHIT gene sequence variants and reduced Fhit protein expression in glioblastoma multiforme.

Authors:  Gulsah Cecener; Berrin Tunca; Unal Egeli; Ahmet Bekar; Gulnur Guler; Sahsine Tolunay; Kaya Aksoy
Journal:  Cell Mol Neurobiol       Date:  2009-09-17       Impact factor: 5.046

3.  Oncosuppressor proteins of fragile sites are reduced in cervical cancer.

Authors:  Enrico Giarnieri; Nicola Zanesi; Arianna Bottoni; Mauro Alderisio; Ankica Lukic; Aldo Vecchione; Vincenzo Ziparo; Carlo Maria Croce; Rita Mancini
Journal:  Cancer Lett       Date:  2009-08-22       Impact factor: 8.679

4.  Novel missense mutation in FHIT gene: interpreting the effect in HPV-mediated cervical cancer in Indian women.

Authors:  Md Kausar Neyaz; Showket Hussain; Md Imtaiyaz Hassan; Bhudev C Das; Syed Akhtar Husain; Mausumi Bharadwaj
Journal:  Mol Cell Biochem       Date:  2010-02       Impact factor: 3.396

5.  Loss of fragile histidine triad protein in human hepatocellular carcinoma.

Authors:  Po Zhao; Xin Song; Yuan-Yuan Nin; Ya-Li Lu; Xiang-Hong Li
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

Review 6.  Fragile histidine triad protein: structure, function, and its association with tumorogenesis.

Authors:  Md Imtaiyaz Hassan; Abdullah Naiyer; Faizan Ahmad
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-24       Impact factor: 4.553

7.  Impaired FHIT expression characterizes serous ovarian carcinoma.

Authors:  K Ozaki; T Enomoto; K Yoshino; M Fujita; G S Buzard; K Kawano; M Yamasaki; Y Murata
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

Review 8.  The molecular genetics of cervical carcinoma.

Authors:  P A Lazo
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

9.  Abnormal FHIT expression profiles in cervical intraepithelial neoplastic (CIN) lesions.

Authors:  G Terry; L Ho; P Londesborough; J Cuzick
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

10.  Reduction in the copy number and expression level of the recurrent human papillomavirus integration gene fragile histidine triad (FHIT) predicts the transition of cervical lesions.

Authors:  Liming Wang; Hui Shen; Bei Feng; Da Zhu; Lan Yu; Xun Tian; Ci Ren; Chun Gao; Xiaomin Li; Ding Ma; Zheng Hu; Hui Wang
Journal:  PLoS One       Date:  2017-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.